• Price (EUR)36.05
  • Today's Change-2.60 / -6.72%
  • Shares traded7.91k
  • 1 Year change-19.48%
  • Beta--
Data delayed at least 15 minutes, as of Jul 01 2022 07:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Walgreens Boots Alliance, Inc. is a holding company. The Company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment consists of the Walgreen Co. (Walgreens) business, which includes the operation of retail drugstores, care clinics and providing specialty pharmacy services. The Retail Pharmacy International segment consists primarily of the pharmacy-led health and beauty retail businesses and optical practices. The Pharmaceutical Wholesale segment consists of equity method investment in AmerisourceBergen. The Company's portfolio of retail and business brands includes Walgreens, Duane Reade, Boots, as well as global health and beauty product brands, including No7, NICE!, Soap & Glory, Liz Earle, Finest Nutrition, Botanics, Well Beginnings, Sleek MakeUP and YourGoodSkin.

  • Revenue in USD (TTM)134.52bn
  • Net income in USD5.11bn
  • Incorporated2014
  • Employees202.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
WBA:NSQ since
GEHE Pharma Handel Alliance Healthcare Deutschland JVAnnounced30 Nov 202130 Nov 2021Announced-16.32%--
The Medicine Cabinet IncDeal completed29 Oct 202129 Oct 2021Deal completed-18.13%390.00k
VillageMD Chicago LLCDeal completed14 Oct 202114 Oct 2021Deal completed-18.41%5.20bn
CareCentrix IncAnnounced14 Oct 202114 Oct 2021Announced-18.41%330.00m
Evolent Health IncRumoured29 Sep 202129 Sep 2021Rumoured-19.82%--
Data delayed at least 15 minutes, as of Jul 01 2022 21:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.